Bioinspired Anti‐VEGF Peptide Nanoparticle with Immune Regulating and Corneal Epithelium Penetration Capability for Corneal Neovascularization Therapy
Source abstract
Abstract
ABSTRACT Corneal neovascularization (CorNV), a leading cause of blindness, is notoriously difficult to treat because of the cornea's tight epithelial barrier and the accompanying inflammatory environment. Current therapies suffer from poor penetration and inadequate management of inflammation. To overcome these challenges, we developed a novel bioinspired nanoparticle. A VEGF‐inhibiting peptide was co‐assembled with Cu 2 + for stability and then modified with a reactive oxygen species (ROS) scavenger and a cell‐penetrating peptide. This multi‐functional design enables deep corneal penetration and targeted action. The resulting nanoparticle significantly prolongs ocular retention to 70 min. It achieved a remarkable penetration depth of 300 µm in a 3D corneal model, ensuring delivery to the site of disease. The nanoparticle demonstrated a dual mechanism of action; it effectively scavenged 60.31% of excess ROS and downregulated inflammation, reducing pro‐inflammatory macrophage polarization. This reshaped the immune microenvironment and potently suppressed angiogenesis, achieving 60.45% growth inhibition in the 3D model. In an animal model, the treatment successfully reduced abnormal blood vessel growth, with immunofluorescence confirming significantly lower expression of key inflammatory markers. This work presents a simple yet highly efficient strategy for deep ocular drug delivery, offering a potent therapeutic approach for CorNV and other oxidative stress‐ and inflammation‐related eye diseases.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Corneal Surgery and Treatments · Advanced Drug Delivery Systems · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Polymeric Materials Tongji University of Materials Science and Engineering Shanghai China
Department of Ophthalmology Zhongshan Hospital Shanghai China
College of Electronic and Information Engineering Tongji University Shanghai China
School of Materials Science and Engineering East China University of Science and Technology Shanghai China
Funding
National Natural Science Foundation of China · Shanghai Rising-Star Program · Fundamental Research Funds for the Central Universities
References (50)
Show source-provided references
1. 10.1016/j.preteyeres.2019.07.00110.1016/j.preteyeres.2019.07.001 ↗
2. 10.1016/j.exer.2021.10845710.1016/j.exer.2021.108457 ↗
3. 10.1038/s41467‐022‐31981‐210.1038/s41467‐022‐31981‐2 ↗
4. 10.1038/s41573‐023‐00671‐z10.1038/s41573‐023‐00671‐z ↗
5. 10.1002/jcp.2169810.1002/jcp.21698 ↗
6. 10.1016/j.survophthal.2011.08.00110.1016/j.survophthal.2011.08.001 ↗
7. 10.1177/1080768325137055110.1177/10807683251370551 ↗
8. 10.1186/s11671‐025‐04234‐610.1186/s11671‐025‐04234‐6 ↗
9. 10.1021/acsnano.8b0203710.1021/acsnano.8b02037 ↗
10. 10.1002/advs.20190061010.1002/advs.201900610 ↗
11. 10.1038/s41467‐023‐42374‐410.1038/s41467‐023‐42374‐4 ↗
12. 10.1126/sciadv.adx015310.1126/sciadv.adx0153 ↗
13. 10.1126/sciadv.ado174910.1126/sciadv.ado1749 ↗
14. 10.1126/sciadv.abn700610.1126/sciadv.abn7006 ↗
15. Electrodeposited Superhydrophilic‐Superhydrophobic Composites for Untethered Multi‐Stimuli‐Responsive Soft Millirobots
16. 10.1021/jacs.4c0375110.1021/jacs.4c03751 ↗
17. Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious Cycle
18. 10.1038/sigtrans.2017.1010.1038/sigtrans.2017.10 ↗
19. 10.1016/j.cej.2021.12908110.1016/j.cej.2021.129081 ↗
20. 10.1038/s41467‐024‐52609‐710.1038/s41467‐024‐52609‐7 ↗
21. 10.1038/s43586‐024‐00320‐810.1038/s43586‐024‐00320‐8 ↗
22. 10.1038/s41467‐024‐54265‐310.1038/s41467‐024‐54265‐3 ↗
23. 10.1038/nrd259110.1038/nrd2591 ↗
24. 10.1038/ncomms844910.1038/ncomms8449 ↗
25. 10.1038/s41578‐024‐00684‐z10.1038/s41578‐024‐00684‐z ↗
26. 10.1038/s41563‐024‐02114‐510.1038/s41563‐024‐02114‐5 ↗
27. 10.1038/s41563‐023‐01481‐910.1038/s41563‐023‐01481‐9 ↗
28. 10.1002/adma.20241103010.1002/adma.202411030 ↗
29. 10.1038/s41578‐022‐00529‐710.1038/s41578‐022‐00529‐7 ↗
30. 10.1039/C9TB00170K10.1039/C9TB00170K ↗
31. 10.1038/s41467‐024‐49825‐610.1038/s41467‐024‐49825‐6 ↗
32. 10.1038/s41563‐025‐02299‐310.1038/s41563‐025‐02299‐3 ↗
33. 10.1016/j.addr.2023.11489910.1016/j.addr.2023.114899 ↗
34. 10.1021/acs.molpharmaceut.8b0021510.1021/acs.molpharmaceut.8b00215 ↗
35. 10.1038/nature0942110.1038/nature09421 ↗
36. 10.1089/jop.2012.020310.1089/jop.2012.0203 ↗
37. 10.1038/nm159110.1038/nm1591 ↗
38. 10.1038/nrm191110.1038/nrm1911 ↗
39. 10.1016/j.biomaterials.2010.11.03310.1016/j.biomaterials.2010.11.033 ↗
40. 10.1002/adma.20230837710.1002/adma.202308377 ↗
41. 10.1038/s41565‐023‐01453‐910.1038/s41565‐023‐01453‐9 ↗
42. 10.1038/s41551‐024‐01208‐410.1038/s41551‐024‐01208‐4 ↗
43. 10.1002/adma.20221141510.1002/adma.202211415 ↗
44. 10.1126/sciadv.abq310410.1126/sciadv.abq3104 ↗
45. 10.1016/j.jconrel.2021.04.00810.1016/j.jconrel.2021.04.008 ↗
46. 10.1038/s41467‐023‐40300‐210.1038/s41467‐023‐40300‐2 ↗
47. 10.1038/s41467‐023‐42509‐710.1038/s41467‐023‐42509‐7 ↗
48. 10.1126/sciadv.ado479110.1126/sciadv.ado4791 ↗
49. 10.1002/adfm.20180184010.1002/adfm.201801840 ↗
50. 10.1182/blood.202201751410.1182/blood.2022017514 ↗